“For many cell-based therapies, progress comes from connecting the right pieces at the right moment,” Klein said. “When ...
– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...
The Science Advances publication details Cellgorithm™, a CRISPR-based technology that gives researchers greater control over gene activity and sets the stage for future applications in stem cell ...
SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results